Eskens F A L M
1Department of Medical Oncology, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands.
Br J Cancer. 2004 Jan 12;90(1):1-7. doi: 10.1038/sj.bjc.6601401.
Angiogenesis is crucial for tumour growth and the formation of metastases. Various classes of angiogenesis inhibitors that are each able to inhibit one of the various steps of this complex process can be distinguished. Results from clinical studies with these agents are summarised. In general, it has been shown that most angiogenesis inhibitors can be safely administered, but that tumour regressions are rare. Combining angiogenesis inhibitors with cytotoxic chemotherapy can enhance anticancer activity. Recently, some promising data with regard to clinical efficacy have been presented. While performing clinical studies with angiogenesis inhibitors, defining biological activity is crucial, but thus far no validated techniques are available. It is conceivable that in the near future various classes of angiogenesis inhibitors will be combined in an attempt to further improve antiangiogenic and anticancer activity.
血管生成对于肿瘤生长和转移形成至关重要。可以区分出各类血管生成抑制剂，每一类都能够抑制这一复杂过程的不同步骤。总结了使用这些药物的临床研究结果。总体而言，已表明大多数血管生成抑制剂可以安全给药，但肿瘤消退很少见。将血管生成抑制剂与细胞毒性化疗联合使用可增强抗癌活性。最近，已公布了一些关于临床疗效的有前景的数据。在进行血管生成抑制剂的临床研究时，定义生物学活性至关重要，但迄今为止尚无经过验证的技术可用。可以想象，在不久的将来，各类血管生成抑制剂将联合使用，以进一步提高抗血管生成和抗癌活性。
